125,013 results match your criteria hepatocellular carcinoma

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade.

Transl Oncol 2021 May 8;14(8):101116. Epub 2021 May 8.

Department of anesthesiology, Linyi Central Hospital, Shandong 276400, China. Electronic address:

Bcl-2 family proteins play critical roles in regulating lymphocyte development and maintain homeostasis, and have also been proved to be involved in various cancer types development. However, the role of Bcl-2 in hepatocellular carcinoma (HCC) development has not been clearly studied. Here, we reported the pan-Bcl-2 inhibitor, obatoclax could directly inhibit HCC growth in vitro. Read More

View Article and Full-Text PDF

Hepatic hilar and celiac plexus nerve blocks as analgesia for doxorubicin-eluting bead embolization procedures for hepatocellular carcinoma: A non-blinded randomized clinical trial.

J Vasc Interv Radiol 2021 May 8. Epub 2021 May 8.

Department of Radiodiagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt.

Purpose: To investigate whether hepatic hilar and celiac plexus nerve blocks provide safe and effective analgesia to patients undergoing doxorubicin-eluting embolics embolization for hepatocellular carcinoma MATERIALS AND METHODS: In this prospective, randomized trial, 92 patients undergoing drug-eluting embolics transarterial chemoembolization (TACE) for hepatocellular carcinoma were enrolled. The control group received standard intraprocedural local anesthetic, intraarterial lidocaine, and intravenous analgesia; the study group (HHCB) underwent hepatic hilar and celiac plexus nerve blockade in addition. Intraarterial lidocaine, intravenous and postprocedural oral narcotics and antiemetics requirements, pain, patient satisfaction, adverse events, and hospital stay were compared. Read More

View Article and Full-Text PDF

A Multimodality-Contribution-Aware TripNet for Histologic Grading of Hepatocellular carcinoma.

IEEE/ACM Trans Comput Biol Bioinform 2021 May 11;PP. Epub 2021 May 11.

Hepatocellular carcinoma (HCC) is a type of primary liver malignant tumor with a high recurrence rate and poor prognosis even undergoing resection or transplantation. Accurate discrimination of the histologic grades of HCC plays a critical role in the management and therapy of HCC patients. In this paper, we discuss a deep learning-based diagnostic model for HCC histologic grading with multimodal Magnetic Resonance Imaging (MRI) images to overcome the problem of limited well-annotated data and extract the discriminated fusion feature referring to the clinical diagnosis experience of radiologists. Read More

View Article and Full-Text PDF

Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma.

Bosn J Basic Med Sci 2021 Apr 12. Epub 2021 Apr 12.

Department of Epidemiology and Statistics, School of Public Health, Guangxi Medical University, Nanning, China; Key Laboratory of High-Incidence-Tumor Prevention and Treatment, Guangxi Medical University, Ministry of Education, Nanning, China.

Hepatocellular carcinoma (HCC) is a highly malignant tumor. In this study, we sought to identify a novel biomarker for HCC by analyzing transcriptome and clinical data. The R software was used to analyze the differentially expressed genes (DEGs) in the datasets GSE74656 and GSE84598 downloaded from the Gene Expression Omnibus database, followed by a functional annotation. Read More

View Article and Full-Text PDF

MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.

Cell Oncol (Dordr) 2021 May 11. Epub 2021 May 11.

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.

Purpose: Lenvatinib is a long-awaited alternative to Sorafenib for first-line targeted therapy of patients with advanced hepatocellular carcinoma (HCC). However, resistance to Lenvatinib results in tumor progression and has become a major obstacle to improving the prognosis of HCC patients. Exploring the mechanisms underlying Lenvatinib resistance is considered essential for the treatment of advanced HCC. Read More

View Article and Full-Text PDF

Software-based planning of ultrasound and CT-guided percutaneous radiofrequency ablation in hepatic tumors.

Int J Comput Assist Radiol Surg 2021 May 11. Epub 2021 May 11.

Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.

Objectives: Radiofrequency ablation (RFA) can be associated with local recurrences in the treatment of liver tumors. Data obtained at our center for an earlier multinational multicenter trial regarding an in-house developed simulation software were re-evaluated in order to analyze whether the software was able to predict local recurrences.

Methods: Twenty-seven RFA ablations for either primary or secondary hepatic tumors were included. Read More

View Article and Full-Text PDF

CT Characterization of Aggressive Macrotrabecular-Massive Hepatocellular Carcinoma: A Step Forward to Personalized Medicine.

Radiology 2021 May 11:210379. Epub 2021 May 11.

From the Departments of Radiology (J.H.Y.) and Pathology (H.K.), Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehak-ro, Jongro-Gu, Seoul 03080, South Korea.

View Article and Full-Text PDF

Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.

Radiology 2021 May 11:203614. Epub 2021 May 11.

From the Departments of Radiology (Z.F., H.L., H.Z., Y.J., Q.L., W.W., P.R.) and Pathology (Q.C.), The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, China.

Background Macrotrabecular-massive (MTM) subtype and vessels encapsulating tumor clusters (VETC) pattern of hepatocellular carcinoma (HCC) are associated with unfavorable prognosis. Purpose To estimate the potential of preoperative CT in the prediction of MTM subtype and VETC pattern. Materials and Methods Patients who underwent surgical resection or liver transplant and preoperative CT for HCC between January 2015 and June 2018 were retrospectively included in the primary cohort. Read More

View Article and Full-Text PDF

A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: Application to healthy liver, diseased tissue, and hepatocellular carcinoma.

Magn Reson Med 2021 May 11. Epub 2021 May 11.

Division of Cancer Sciences, Quantitative Biomedical Imaging Laboratory, University of Manchester, Manchester, UK.

Purpose: We introduce a novel, generalized tracer kinetic model selection framework to quantify microvascular characteristics of liver and tumor tissue in gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI).

Methods: Our framework includes a hierarchy of nested models, from which physiological parameters are derived in 2 regimes, corresponding to the active transport and free diffusion of gadoxetate. We use simulations to show the sensitivity of model selection and parameter estimation to temporal resolution, time-series duration, and noise. Read More

View Article and Full-Text PDF

Deregulation of cell cycle and related microRNA expression induced by vinyl chloride monomer in hepatocytes of rats.

Toxicol Ind Health 2021 May 11:7482337211015591. Epub 2021 May 11.

Department of Toxicology, School of Public Health, Shanxi Medical University, Taiyuan, China.

Vinyl chloride (VC) is a confirmed human carcinogen associated with hepatocellular carcinoma and angiosarcoma. However, the role of microRNAs (miRNAs) in liver cell cycle changes under VC exposure remains unclear, which prevents research on the mechanism of VC-induced carcinogenesis. In this study, male rats were injected intraperitoneally with VC (0, 5, 25, and 125 mg/kg body weight) for 6, 8, and 12 weeks. Read More

View Article and Full-Text PDF

Knockdown of CENPW Inhibits Hepatocellular Carcinoma Progression by Inactivating E2F Signaling.

Technol Cancer Res Treat 2021 Jan-Dec;20:15330338211007253

Department of Infectious Diseases, Qingdao No.6 People's Hospital, Qingdao, Shandong, People's Republic of China.

Aim: This study aimed to evaluate the effects of centromere protein W (CENPW, also known as CUG2) in hepatocellular carcinoma (HCC).

Methods: CENPW expression in HCC tissues and cells was detected by RT-qPCR assay. CCK-8 and colony formation assay were used to assess cell proliferation. Read More

View Article and Full-Text PDF

FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib.

Oncologist 2021 May 11. Epub 2021 May 11.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration.

On March 10, 2020, the FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The recommended approved dosage was nivolumab 1 mg/kg intravenously (IV) plus ipilimumab 3 mg/kg IV every 3 weeks for four cycles, followed by nivolumab 240 mg IV every 2 weeks. The approval was based on data from Cohort 4 of CHECKMATE-040, which randomized patients with advanced unresectable or metastatic HCC previously treated with or who were intolerant to sorafenib to receive one of three different dosing regimens of nivolumab in combination with ipilimumab. Read More

View Article and Full-Text PDF

CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Clin Pract (Lond) 2021 ;18(2):1626-1632

Department of Surgery, Liver Transplantation Institute, Inonu University, Turkey.

Background: Inflammation and its markers are considered prognostically important for many cancers, including Hepatocellular Carcinoma (HCC). However, it is not really clear which markers are the best.

Aims: To assess in a cohort of prospectively-evaluated HCC patients who were treated with liver transplant and whose survival was known, multiple commonly used inflammatory markers in relation to survival and to both clinical and tumor aggressiveness parameters. Read More

View Article and Full-Text PDF
January 2021

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.

Br J Cancer 2021 May 10. Epub 2021 May 10.

Medical Oncology Department, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.

Background: This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET overexpression.

Methods: In Phase 2b, tepotinib was orally administered once daily (300, 500 or 1,000 mg) to Asian adults with aHCC. The primary endpoints were dose-limiting toxicities (DLTs) and adverse events (AEs). Read More

View Article and Full-Text PDF

FMRP regulates STAT3 mRNA localization to cellular protrusions and local translation to promote hepatocellular carcinoma metastasis.

Commun Biol 2021 May 10;4(1):540. Epub 2021 May 10.

Cancer Metastasis Alert and Prevention Center, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, National & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, China.

Most hepatocellular carcinoma (HCC)-associated mortalities are related to the metastasis of cancer cells. The localization of mRNAs and their products to cell protrusions has been reported to play a crucial role in the metastasis. Our previous findings demonstrated that STAT3 mRNA accumulated in the protrusions of metastatic HCC cells. Read More

View Article and Full-Text PDF

Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.

Ann Transplant 2021 May 11;26:e930383. Epub 2021 May 11.

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

BACKGROUND Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) results in poor survival outcome. This study assessed the clinical outcomes of pulmonary metastasectomy in LT recipients with pulmonary metastasis of HCC in a high-volume transplant center and analyzed factors prognostic of survival following metastasectomy. MATERIAL AND METHODS This study analyzed outcomes in 52 patients who underwent pulmonary resection due to pulmonary metastasis as the first recurrence of HCC after LT from January 2004 to December 2017 in a single center. Read More

View Article and Full-Text PDF

Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation.

Infect Agent Cancer 2021 May 10;16(1):28. Epub 2021 May 10.

Biological Cell Therapy Research Center, Puren Hospital Affiliated to Wuhan University of Science and Technology, 430081, Wuhan, China.

Background: Early diagnosis can significantly improve treatment outcomes for hepatocellular carcinoma (HCC) patients. Currently, the dosage of serum alpha fetoprotein (AFP) is widely used in the diagnosis of HCC, but this biomarker has low specificity and may cause false positive or false negative results. Thus, it's necessary to find and validate other serum tumor markers that in association for AFP would increase the sensitivity and the specificity in the HCC diagnosis. Read More

View Article and Full-Text PDF

Mixed pancreatic hepatoid carcinoma: A surgical case report and literature review.

Int J Surg Case Rep 2021 Apr 30;83:105951. Epub 2021 Apr 30.

Department of Gastrointestinal and Hepato-pancreato-biliary surgery, Bach Mai Hospital, Hanoi, Viet Nam.

Background: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shared similar features of morphology and immunohistochemistry with hepatocellular carcinoma (HCC). Pancreatic HC exists as either pure or mixed type. Mixed pancreatic HC is extremely rare, with only a few cases reported in the literature to date. Read More

View Article and Full-Text PDF

Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma.

Lancet Gastroenterol Hepatol 2021 May 7. Epub 2021 May 7.

Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London W12 0HS, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

View Article and Full-Text PDF

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Gastroenterol Hepatol 2021 May 7. Epub 2021 May 7.

Department of Intervention, Fujian Cancer Hospital, Fuzhou, China.

Background: Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR inhibitors have been done in populations with a high prevalence of hepatitis B virus infection. The aim of this study was to evaluate the efficacy and safety of apatinib in patients with pretreated advanced hepatocellular carcinoma.

Methods: AHELP was a randomised, double-blind, placebo-controlled, phase 3 trial done at 31 hospitals in China, in patients (aged ≥18 years) with advanced hepatocellular carcinoma who had previously been refractory or intolerant to at least one line of systemic chemotherapy or targeted therapy. Read More

View Article and Full-Text PDF

PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.

Cell Cycle 2021 May 10:1-11. Epub 2021 May 10.

Department of Minimally Invasive Intervention, Shaanxi Provincial Cancer Hospital, Xi'an, China.

Increasing proofs have declared that liver cancer stem cells (CSCs) are the main contributors to tumor initiation, metastasis, therapy resistance, and recurrence of hepatocellular carcinoma (HCC). However, the molecular mechanisms underlying CSCs regulation remain largely unclear. Recently, PCNA-associated factor (PAF) was identified to play a key role in maintaining breast cancer cell stemness, but its role in liver cancer stem cells has not been declared yet. Read More

View Article and Full-Text PDF

TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma.

Cancer Sci 2021 May 10. Epub 2021 May 10.

Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Ten-eleven translocation 1 (TET1) is an essential methylcytosine dioxygenase of the DNA demethylation pathway. Despite its dysregulation being known to occur in human cancer, the role of TET1 remains poorly understood. In this study, we report that TET1 promotes cell growth in human liver cancer. Read More

View Article and Full-Text PDF

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.

Eur J Clin Invest 2021 May 10:e13583. Epub 2021 May 10.

University of Ioannina, Ioannina, Greece.

Background: Cancers of unknown primary (CUP) are highly aggressive tumours with limited molecular characterization. These tumours can be particularly sensitive to immune checkpoint inhibitors (ICI) by mounting a seemingly more effective anti-tumour immune response. Unlike other tumour lineages, the biological basis and clinical efficacy of ICI in CUP remain largely unknown. Read More

View Article and Full-Text PDF

Laparoscopic partial liver resection for hepatocellular carcinoma arising from Fontan-associated liver disease: a case report.

Surg Case Rep 2021 May 10;7(1):115. Epub 2021 May 10.

Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.

Background: The Fontan procedure (FP) is a palliative surgery for functional single ventricle. The Fontan circulation maintains pulmonary circulation by a high central venous pressure, leading to chronic congestive liver. The number of patients diagnosed with hepatocellular carcinoma (HCC) arising from liver fibrosis and cirrhosis after FP is increasing. Read More

View Article and Full-Text PDF

Effects of Bacillus subtilis iturin A on HepG2 cells in vitro and vivo.

AMB Express 2021 May 10;11(1):67. Epub 2021 May 10.

Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, 127 Youyi West Road, Xi'an, 710072, Shaanxi, China.

Iturin A with cyclic peptide and fatty acid chain isolated from Bacillus subtilis fermentation shows a variety of biological activities. Among them, the anticancer activity attracted much attention. However, the molecular mechanism of its inhibitory effect on hepatocellular carcinoma was still unclear. Read More

View Article and Full-Text PDF

A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.

Biomater Sci 2021 May 10. Epub 2021 May 10.

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China. and Fujian Institute of Research on The Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China.

T-lymphocytes play a potent role in cancer immunotherapy; while, limited tumor infiltrating lymphocytes (TILs) combined with severe immunosuppression always significantly hinder their antitumor immune responses, especially in solid tumors such as hepatocellular carcinoma (HCC). Here, we prepared a highly stable multifunctional aptamer for strengthening antitumor immunity against HCC solid tumors through a dual immune checkpoint blockade of CTLA-4 and PD-L1. The engineered multifunctional aptamer (termed P1/C4-bi-apt) can block both CTLA-4/B7 and PD-1/PD-L1 signaling pathways and thus enhance the antitumor immune responses. Read More

View Article and Full-Text PDF

Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.

Acta Radiol 2021 May 8:2841851211014194. Epub 2021 May 8.

Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Medical Imaging, Shanghai, PR China.

Background: Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has been widely used in clinical practice. However, scientific evidence is lacking for recommending a particular sequence for measuring tumor size.

Purpose: To retrospectively compare the size of hepatocellular carcinoma (HCC) measured on different gadoxetic acid-enhanced MRI sequences using pathology as a reference. Read More

View Article and Full-Text PDF

Amplification of DDR2 mediates Sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.

Cell Biol Int 2021 May 9. Epub 2021 May 9.

Department of Hepatobiliary Surgery the First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, P.R.China.

Sorafenib was the first systemic therapy approved by the food and drug administration (FDA) to treat advanced hepatocellular carcinoma (HCC). However, Sorafenib therapy is frequently accompanied by drug resistance. We aimed to explore the mechanisms of Sorafenib resistance and provide feasible solutions to increase the response to Sorafenib in patients with advanced HCC. Read More

View Article and Full-Text PDF

Therapeutic vaccination for treatment of Chronic Hepatitis B.

Clin Exp Immunol 2021 May 9. Epub 2021 May 9.

Peter Medawar Building for Pathogen Research, University of Oxford.

Chronic hepatitis B infection remains a serious global health threat, contributing to large numbers of deaths through liver cirrhosis and hepatocellular carcinoma. Current treatment does not eradicate disease and therefore new treatments are urgently needed. In acute HBV a strong immune response is necessary to clear the virus, but in chronic infection the immune response is weakened and dysfunctional. Read More

View Article and Full-Text PDF

Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis.

Ann Surg Oncol 2021 May 9. Epub 2021 May 9.

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Academia Level 5, 20 College Road, Singapore, 169856, Singapore.

Background: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver with high rates of recurrence post-resection. Repeat hepatectomy (RH) and radiofrequency ablation (RFA) are the mainstays for managing recurrent HCC following initial curative resection. This retrospective study aims to determine the average treatment effect of RH and RFA in patients with recurrent HCC. Read More

View Article and Full-Text PDF